RESULTS	Of patients who received adalimumab 40 mg eow for 5 years , 26.1 % achieved clinical remission ( Disease Activity Score 28-joint count < 2.6 ) , had no radio graphic progression ( change in modified total Sharp score 0.5 ) , and had normal function ( Health Assessment Questionnaire 0.5 ) , versus 11.9 % of those who initially received placebo .\